Status:
COMPLETED
Seroquel® Combined With Cognitive Remediation Therapy to Conventional Treatment in Patients With Schizophrenia
Lead Sponsor:
AstraZeneca
Conditions:
Schizophrenia
Eligibility:
All Genders
18-64 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to compare efficacy of quetiapine fumarate combined with Cognitive Remediation Therapy (CRT) to conventional treatment by evaluating change in social outcome in patients w...
Eligibility Criteria
Inclusion
- Signed informed consent
- Documented clinical diagnosis of schizophrenia or schizoaffective disorder for at least 2 years.
- Clinically stable and in an outpatient setting before entering the study (visit 1).
Exclusion
- Use of clozapine and quetiapine within two months prior to visit 1.
- If total points are ≤ 55 Intelligence quotient (IQ) according to score of WAIS-III test at visit 1.
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
85 Patients enrolled
Trial Details
Trial ID
NCT00255515
Start Date
September 1 2005
End Date
December 1 2007
Last Update
March 25 2009
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Eskilstuna, Sweden
2
Research Site
Gothenburg, Sweden
3
Research Site
Hisingsbacka, Sweden
4
Research Site
Huddinge, Sweden